Educational use only
This page is not medical advice and does not provide instructions for using, injecting, compounding, or buying Epitalon. U.S. readers should treat online anti-aging protocols as unverified unless a licensed clinician and regulator can support the specific product and use.
Identity snapshot
| Common names | Epitalon, Epithalon, Epithalone, AEDG |
|---|---|
| Sequence | AEDG - Ala-Glu-Asp-Gly |
| Type | Synthetic tetrapeptide in the Khavinson short-peptide catalog |
| Stated target in Khavinson table | Neuroendocrine system |
| Common confusion | Epithalamin, Endoluten, and pineal-gland supplement names |
Epitalon vs Epithalamin
Epitalon is a defined synthetic tetrapeptide. Epithalamin is a pineal-gland peptide complex from the older Russian clinical-preparation lineage. They are related historically, but they are not interchangeable identities. A paper about Epithalamin is not automatically evidence for synthetic AEDG, and a vendor listing for AEDG is not proof that the material matches a historical clinical preparation.
Endoluten adds another layer of confusion. It is usually presented as a Cytomax natural peptide-complex product for the pineal gland. That makes it a product-family term, not a synonym for the isolated AEDG sequence.
Evidence map
Epitalon research clusters around cellular gene-expression work, histone/DNA interaction hypotheses, animal aging models, retinal and neural differentiation studies, melatonin-related pineal work, and older Khavinson-network human observations. The most durable identity fact is the sequence: AEDG.
Claim-safety rule: "researched for telomerase or melatonin effects" is defensible source-map language. "Proven to reverse aging" is not supported by the evidence standard this site uses.
The 2020 Molecules paper on AEDG reports in-vitro stem-cell gene-expression and protein-synthesis findings. That is mechanistic research, not a clinical protocol. Older life-extension and cancerogenesis claims are concentrated in the same research tradition and need independent replication before they should be used as health guidance.
A 2025 Biogerontology cell-line paper reported telomere-length changes in normal human cells and breast-cancer cell lines through telomerase-related or ALT-related mechanisms. That makes telomerase claims a safety-sensitive research topic, not a reason to treat Epitalon as a proven anti-aging intervention.
Epitalon benefits from studies, dosage from studies, and side effects
Common searches ask for Epitalon benefits, Epithalon dosage, Epitalon side effects, FDA status, and legal status. This is not an Epitalon dosage protocol page. It is a study-context page: when a dose or exposure is mentioned, it is reported only as an academic study condition, not as a consumer protocol.
| Source context | Study-only dose or exposure | Reported endpoint | Interpretation limit |
|---|---|---|---|
| 2020 Molecules in-vitro AEDG paper | Human gingival mesenchymal stem cells treated with AEDG at 0.01 ug/mL for one week. | Neurogenic marker gene expression and protein-synthesis endpoints. | Cell-culture exposure; not a human Epitalon dosage. |
| 2014 Khavinson short-peptide table | No consumer dose; identifies Epithalon/AEDG as Ala-Glu-Asp-Gly. | Neuroendocrine-system activity category, not a measured benefit endpoint. | Identity and research taxonomy, not benefit proof or prescribing guidance. |
| Epithalamin cohort literature | Pineal extract context, not synthetic AEDG dosage. | Mortality and aging-related observational endpoints in older cohorts. | Related historical preparation; not interchangeable with Epitalon. |
Side-effect information cannot be generalized from a sequence name alone. A commercial product may differ by route, purity, sterility, salt form, storage, excipients, concentration, and labeling. That is why this page discusses safety caveats and FDA status at the category level instead of giving risk estimates for unverified products.
FDA status and legal status
Epitalon FDA status and Epitalon legal status searches should start with approved-drug databases and specific product labels. FDA approval, compounding, research-use labeling, Russian clinical history, and supplement catalog listings are separate issues. The FDA states that compounded drugs are not FDA-approved and are not verified by FDA for safety, effectiveness, or quality before marketing. That general point matters for any online peptide discussion where product identity and route of administration are uncertain.
This page does not identify an FDA-approved Epitalon drug for the United States. It also does not evaluate any vendor, vial, capsule, spray, or "research" product.
Sources
- Khavinson, "Peptides, Genome, Aging" (2014) - source for the AEDG/Epithalon entry in the short-peptide table.
- AEDG Peptide (Epitalon) study, Molecules 2020 - mechanism-focused stem-cell paper.
- PubMed record for the 2020 AEDG paper.
- Biogerontology 2025 Epitalon telomere-length cell-line paper - safety-sensitive telomerase/ALT context.
- FDA: how to check whether a drug is approved - legal-status verification context.
- FDA compounding Q&A - U.S. safety and approval context.